Q2 2025 Earnings Call Transcript August 7, 2025 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to trac ...

BioCryst Pharmaceuticals BCRX is slated to report its second-quarter 2025 results on Aug. 4, before the opening bell. The ...

In July 2025, Novartis Pharmaceuticals announced a phase III study to assess efficacy and safety of crizanlizumab (5 mg/kg) ...

From the November 2002 edition of Optus. The Soundtrack Channel (STC) is not listed, and is also not listed in the January issue, but is listed in the August 2002 issue. That probably explains why I ...

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty ratings firms that are covering the stock ...

Investors considering a purchase of Intellia Therapeutics Inc (Symbol: NTLA) stock, but tentative about paying the going market price of $13.21/share, might benefit from considering selling puts ...

As we await word on the revival series, we look back at the efforts made in 2002 to bring a Buffy the Vampire Slayer animated series to life.